Recurrence in NMIBC

  • Sanchia S. GoonewardeneEmail author
  • Raj Persad
  • Hanif Motiwala
  • David Albala


European Association of Urology (EAU) guidelines recommend a follow-up transurethral resection of bladder tumors (reTUR-B) for intermediate and high-risk non-muscle invasive bladder cancer (NMIBC) 2–6 weeks after the initial resection (Merseburger et al. in Curr Opin Urol 18(5):513–518, 2008). This chapter covers recurrence in NMIBC


  1. Busato Júnior WF, Almeida GL, Ribas CA, Ribas Filho JM, De Cobelli O. EORTC risk model to predict progression in patients with non-muscle-invasive bladder cancer: is it safe to use in clinical practice? Clin Genitourin Cancer. 2016;14(2):176–82.CrossRefGoogle Scholar
  2. Hartinger J, Häußermann R, Olbert P, Hofmann R, Hegele A. Predictors for presence of residual tumor in follow-up transurethral resection of bladder tumors: single center results. Urologe A. 2013;52(4):557–61.CrossRefGoogle Scholar
  3. Luján S, Santamaría C, Pontones JL, Ruiz-Cerdá JL, Trassierra M, Vera-Donoso CD, Solsona E, Jiménez-Cruz F. Risk estimation of multiple recurrence and progression of non muscle invasive bladder carcinoma using new mathematical models. Actas Urol Esp. 2014;38(10):647–54.CrossRefGoogle Scholar
  4. Merseburger AS, Matuschek I, Kuczyk MA. Bladder preserving strategies for muscle-invasive bladder cancer. Curr Opin Urol. 2008;18(5):513–8.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Sanchia S. Goonewardene
    • 1
    Email author
  • Raj Persad
    • 2
  • Hanif Motiwala
    • 3
  • David Albala
    • 4
  1. 1.East of England DeaneryNorfolk and Norwich University HospitalNorwichUK
  2. 2.North Bristol NHS TrustBristolUK
  3. 3.Southend University HospitalWestcliff-on-SeaUK
  4. 4.Boston UniversityBostonUSA

Personalised recommendations